This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

37/100

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a debated model of Alzheimer disease pathogenesis.1 Only patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease are eligible for lecanemab treatment.Although approved for use in Canada effective January 2026, 2 Canada's Drug Agency and Quebec's Institut national d'excellence en santé et en services sociaux recommended against public reimbursement; coverage may differ across jurisdictions.3,4 Patient eligibility depends on clinical, laboratory, and diagnostic imaging criteria.1,5 Eligibility and treatment pathways may differ across Canada.A typical pathway is shown in Figure 1.Initial clinical eligibility will likely be determined in primary care settings where cognitive changes are first uncovered.6 A specialist (i.e., cognitive neurologist, geriatric psychiatrist, or geriatrician) will determine eligibility with APOE genotyping and confirmation of amyloid positivity by lumbar puncture for cerebrospinal fluid (CSF) or positron emission tomography (PET), and coordin ate infusions and follow-up.Blood-based biomarkers are not currently approved for confirming eligibility because of their limited accuracy.7 Providers should engage patients and caregivers in shared decision-making, weighing potential risks and benefits.5,6 A proposed shared decision-making pathway is provided in Appendix 1, available at www.cmaj.ca/lookup

Key findings

Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a debated model of Alzheimer disease pathogenesis.1 Only patients with mild cog

Why it matters

Lecanemab is a monoclonal antibody that binds soluble brain amyloid-β and slows the underlying disease process, and it is approved in Canada for patients with mild cognitive impairment or mild dementia due to Alzheimer disease. However, Canada's Drug Agency and Quebec's health agency recommended against public reimbursement, and eligibility requires APOE genotyping and confirmation of amyloid positivity.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 37/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Canadian Medical Association Journal)
Journal's citation record	2 / 4	Canadian Medical Association Journal: journal h-index 230 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Sharon Elizabeth Straus: h-index 114 (OpenAlex, whole career)
Institution's track record	2 / 3	University of Toronto: institution h-index 1,923 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 42373113)
Free to read	2 / 2	Free to read
Total	37 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Weiss, S. M., Watt, J. A., Ewa, V., & Straus, S. E. (2026). Lecanemab use for early Alzheimer disease in Canada. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.260193

Vancouver

Weiss SM, Watt JA, Ewa V, Straus SE. Lecanemab use for early Alzheimer disease in Canada. Canadian Medical Association Journal. 2026. doi:10.1503/cmaj.260193. PMID: 42373113.

BibTeX

@article{weiss2026-42373113,
  author  = {Weiss, Sophie M. and Watt, Jennifer A. and Ewa, Vivian and Straus, Sharon Elizabeth},
  title   = {{Lecanemab use for early Alzheimer disease in Canada}},
  journal = {Canadian Medical Association Journal},
  year    = {2026},
  doi     = {10.1503/cmaj.260193},
  pmid    = {42373113},
  url     = {https://doi.org/10.1503/cmaj.260193}
}

Related studies in Treatments

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Treatments

Where this led: Lecanemab on the treatments page — its current status, approval date, side-effect rate and list price, kept up to date.

See all studies in Treatments →